Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2011 on Thursday, March 8, 2012, after market close. Company...
Emergent BioSolutions Provides Preliminary 2011 Financial Results and Provides Guidance for 2012
Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2011 financial results and provided guidance for 2012. For 2011, the Company anticipates total revenues of $270 to $275 million....
Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 study (protocol 16201) of TRU-016 in combination with bendamustine for patients with relapsed chronic lymphocytic...
Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO, Remain as Executive Chairman of the Board of Directors Focused on Corporate Strategy and M&A Opportunities
Emergent BioSolutions Inc. (NYSE: EBS) announced today that Fuad El-Hibri will retire as CEO effective April 1, 2012. Mr. El-Hibri will continue to serve as Executive Chairman of the Board of...
Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott
Emergent BioSolutions Inc. (NYSE:EBS) today announced plans for its TRU-016 program following receipt of a notice from Abbott that it is terminating its co-development and co-commercialization...
Emergent BioSolutions to Participate in January 2012 Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will provide a corporate overview presentation, which may include a discussion of recent...
Emergent BioSolutions Announces Acceptance of Four TRU-016 Abstracts for Presentation at 2011 American Society of Hematology Annual Meeting
Emergent BioSolutions Inc. (NYSE: EBS) announced today that four abstracts on TRU-016 have been accepted for presentation at the 53rd Annual Meeting of the American Society of Hematology (ASH) on...
Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its humanized anti-CD37 mono-specific protein therapeutic, TRU-016, in development for the treatment of B-cell malignancies has been...
Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a pivotal immunogenicity and safety study to evaluate a three-dose vaccination schedule of BioThrax(R) (Anthrax Vaccine...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the third quarter and nine months ended September 30,...
Emergent BioSolutions to Participate in November 2011 Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will provide a corporate overview presentation, which may include a discussion of recent...
Emergent BioSolutions to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 3, 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the third quarter 2011 on Thursday, November 3, 2011, after market...